Carmine Stengone

Carmine Stengone is the President & CEO at Contineum Therapeutics, a clinical-stage biopharmaceutical company focusing on developing novel small molecule therapies for neuroscience, inflammation, and immunology indications. Prior to this role, Carmine held leadership positions at COI Pharmaceuticals, Avelas Biosciences, Afraxis, Phenomix Corporation, Anadys Pharmaceuticals, and Johnson & Johnson Pharmaceutical R&D. Carmine holds an MBA in Finance from Cornell Johnson Graduate School of Management, an MS in Organic Chemistry from Duke University, and a BS in Chemistry from Wake Forest University.